超薄支架西罗莫司洗脱冠状动脉支架治疗动脉粥样硬化病变的安全性和有效性(TALENT):前瞻性多中心随机对照试验
TALENT 为前瞻性、随机、单盲、多中心研究,在欧洲 23 个中心纳入 18 岁及以上、至少一处原生冠状动脉、大隐静脉桥或动脉旁路 conduit 狭窄≥50% 且参考血管直径 2.25–4.50 mm 的患者,按 1:1 随机植入 Supraflex(西罗莫司洗脱、可降解聚合物涂层、超薄支架)或 Xience(依维莫司洗脱、持久聚合物涂层)。主要终点为 12 个月器械导向复合终点(心性死亡、靶血管心肌梗死或临床指征的靶病变血运重建),非劣效界值 4.0%。12 个月时 Supraflex 组 35 例(4.9%)vs Xience 组 37 例(5.3%)发生主要终点(绝对差 -0.3%,单侧 95% 置信上限 1.6%,非劣效 p<0.0001)。两组明确或可能的支架血栓发生率均低且无差异。作者认为 Supraflex 似乎是临床实践中安全有效的替代药物洗脱支架。
要点
- 全部 comers 人群中,12 个月器械导向复合终点 Supraflex 组 4.9%(35 例)vs Xience 组 5.3%(37 例),绝对差 -0.3%(单侧 95% 置信上限 1.6%),非劣效 p<0.0001。
- 非劣效界值设为 4.0%,基于假设 1 年复合终点发生率为 8.3%。
- 两组明确或可能的支架血栓发生率均低且无差异。
- 研究纳入参考血管直径 2.25–4.50 mm、至少一处狭窄≥50% 的患者,涵盖原生冠状动脉、大隐静脉桥或动脉旁路 conduit。
- 作者认为 Supraflex 似乎是临床实践中安全有效的替代药物洗脱支架。
适用人群与场景
- 年龄 18 岁及以上,至少一处原生冠状动脉、大隐静脉桥或动脉旁路 conduit 狭窄≥50%,参考血管直径 2.25–4.50 mm,以全部 comers 方式接受经皮冠状动脉介入治疗的患者。
诊断标准与关键阈值
- 主要终点为非劣效比较 12 个月器械导向复合终点(心性死亡、靶血管心肌梗死或临床指征的靶病变血运重建),非劣效界值 4.0%,基于假设 1 年复合终点发生率为 8.3%。
研究设计与关键结果
- 前瞻性、随机、单盲、多中心研究(TALENT),在欧洲 23 个中心进行;2016 年 10 月 21 日至 2017 年 7 月 3 日随机分配 1435 例患者(1046 处病变)至 Supraflex 组,其中 720 例接受指数操作;715 例患者(1030 处病变)分配至 Xience 组,均接受指数操作。
- 12 个月时主要终点在 Supraflex 组发生 35 例(4.9%),Xience 组 37 例(5.3%),绝对差 -0.3%(单侧 95% 置信上限 1.6%),非劣效 p<0.0001。
- 明确或可能的支架血栓发生率作为安全性指标,两组均低且无差异。
证据类型、等级与局限
- 证据类型:前瞻性、随机、单盲、多中心非劣效性试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为 Supraflex 似乎是临床实践中安全有效的替代药物洗脱支架。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Supraflex is a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts. We aimed to compare Supraflex with the standard of care, Xience, an everolimus-eluting stent with a durable polymer coating, regarding clinical outcomes with a randomised trial in an all-comer population.
METHODS: We did a prospective, randomised, single-blind, multicentre study (TALENT) across 23 centres in Europe (the Netherlands, Poland, the UK, Spain, Bulgaria, Hungary, and Italy). Eligible participants were aged 18 years or older, had one or more coronary artery stenosis of 50% or greater in a native coronary artery, saphenous venous graft, or arterial bypass conduit, and had a reference vessel diameter of 2·25-4·50 mm. Patients underwent percutaneous coronary intervention in an all-comer manner. We randomly assigned patients (1:1) to implantation of either a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts (Supraflex) or an everolimus-eluting stent with a durable polymer coating (Xience). Randomisation was done by local investigators by use of a web-based software with random blocks according to centre. The primary endpoint was a non-inferiority comparison of a device-oriented composite endpoint-cardiac death, target-vessel myocardial infarction, or clinically indicated target lesion revascularisation-between groups at 12 months after the procedure, assessed in an intention-to-treat population. On assumption of 1-year composite endpoint prevalence of 8·3%, a margin of 4·0% was defined for non-inferiority of the Supraflex group compared with the Xience group. This trial is registered with ClinicalTrials.gov, number NCT02870140.
FINDINGS: Between Oct 21, 2016, and July 3, 2017, 1435 patients with 1046 lesions were randomly assigned to Supraflex, of whom 720 received the index procedure, and 715 patients with 1030 lesions were assigned to Xience, all receiving the index procedure. At 12 months, the primary endpoint had occurred in 35 patients (4·9 %) in the Supraflex group and in 37 patients (5·3%) in the Xience group (absolute difference -0·3% [one-sided 95% upper confidence bound 1·6%], pnon-inferiority<0·0001). Definite or probable stent thrombosis prevalence, a safety indicator, was low in both groups and did not differ between them.
INTERPRETATION: The Supraflex stent was non-inferior to the Xience stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. Supraflex seems a safe and effective alternative drug-eluting stent to other stents in clinical practice.
FUNDING: European Cardiovascular Research Institute.
参考来源
- Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019. PMID: 30827782. doi:10.1016/S0140-6736(18)32467-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。